News
-
OptiNose has been selected by the Research Council of Norway for a grant of up to NOK 15.9 million ($1.8 million) to study intranasal delivery of Orexin-A for the treatment of narcolepsy. The grant is… Read more . . .
-
Pulmatrix has announced that a pilot bioequivalence study of 5 formulations of its PUR0200 DPI for the treatment of COPD has begun enrollment. The company is partnered with Mylan on development of the DPI. According… Read more . . .
-
Mast Therapeutics says that top-line results from a Phase 2a study of its AIR001 sodium nitrite inhalation solution for the treatment of heart failure with preserved ejection fraction (HFpEF) demonstrated statistically significant change in pulmonary… Read more . . .
-
The FDA has approved Avanir Pharmaceuticals’ intranasal sumatriptan for the treatment of acute migraines, the company said. The product, which Avanir licensed from OptiNose in 2013, will be marketed in the US as Onzetra Xsail.… Read more . . .
-
Skyepharma has announced agreements with Sanofi and Mundipharma that will transfer Mexican, Central American, and South American development, licensing and marketing rights for the Flutiform fluticasone/formoterol MDI to Mundipharma. Sanofi will continue to manufacture Flutiform… Read more . . .
-
Milestone Pharmaceuticals has announced today that its MSP-2017 intranasal calcium channel antagonist has been assigned the unique non-proprietary name “etripamil” by the United States Adopted Name (USAN) Council. The company is developing the etripamil nasal… Read more . . .
-
Dutch intranasal vaccine developer Mucosis has received €3.7 million from the Wellcome Trust for clinical development of its SynGEM intranasal respiratory syncytial virus (RSV) vaccine, the company said. The money will be used to fund… Read more . . .
-
MannKind Corporation has announced an agreement to develop “multiple inhaled therapeutic products” with a company called Receptor Life Sciences, described as a “newly formed entity.” MannKind says that Receptor will license MannKind’s manufacturing technology and… Read more . . .
-
Neurelis says that it has received guidance from the FDA regarding clinical trial requirements for the company’s NRL-1 intranasal diazepam for the treatment of acute repetitive seizures in epilepsy patients and is now initiating the… Read more . . .
-
Turing Pharmaceuticals said that it has received a no objection letter from Health Canada regarding the initiation of Phase 1 trials of TUR-002 intranasal ketamine for the reduction of suicidal ideations and that it expects… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland